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A B S T R A C T
Aim: To perform a deep phenotype characterisation in a pedigree of 3 siblings with Leigh syndrome and
compound heterozygous NDUFAF6 mutations.
Method: A multi-gene panel of childhood-onset basal ganglia neurodegeneration inherited conditions was
analysed followed by functional studies in fibroblasts.
Results: Three siblings developed gait dystonia in infancy followed by rapid progression to generalised dystonia
and psychomotor regression. Brain magnetic resonance showed symmetric and bilateral cytotoxic lesions in the
putamen and proliferation of the lenticular-striate arteries, latter spreading to the caudate and progressing to
cavitation and volume loss. We identified a frameshift novel change (c.554_558delTTCTT; p.Tyr187AsnfsTer65)
and a pathogenic missense change (c.371T>C; p.Ile124Thr) in the NDUFAF6 gene, which segregated with an
autosomal recessive inheritance within the family. Patient mutations were associated with the absence of the
NDUFAF6 protein and reduced activity and assembly of mature complex I in fibroblasts. By functional com-
plementation assay, the mutant phenotype was rescued by the canonical version of the NDUFAF6. A literature
review of 14 NDUFAF6 patients showed a consistent phenotype of an early childhood insidious onset neuro-
logical regression with prominent dystonia associated with basal ganglia degeneration and long survival.
Interpretation: NDUFAF6-related Leigh syndrome is a relevant cause of childhood onset dystonia and isolated
bilateral striatal necrosis. By genetic complementation, we could demonstrate the pathogenicity of novel genetic
variants in NDUFAF6.
1. Introduction
Leigh syndrome (LS) is a progressive neurodegenerative condition
presenting in infancy, childhood or adolescence [1,2]. Neurologic fea-
tures include psychomotor delay or regression, hypotonia, dystonia,
ataxia, spasticity, seizures and brainstem dysfunction. Early supple-
mentation with thiamine and biotin can modify the clinical course and
improve prognosis in LS patients due to biotinidase deficiency and
genetic defects in thiamine transport and metabolism [3]. Thiamine
responsiveness has also been described in patients with PDHA1
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deficiency presenting at age > 12months with relapsing ataxia and
Leigh syndrome [3–5]. For the rest of aetiologies, the disorder is pro-
gressive, leading to severe disability and early death in most of the
cases [1,6,7].
To date, 89 genetic defects have been reported to cause LS and
Leigh-like syndromes [8–10]. Nicotinamide adenine dinucleotide
(NADH)-ubiquinone oxidoreductase or NADH dehydrogenase (complex
I) deficiency accounts for approximately 35 to 50% of LS patients
[11,12]. Complex I transfers electrons from NADH molecules to ubi-
quinone and pumps protons across the inner mitochondrial membrane
[13–15]. Complex I contains 44 subunits [16–18]. The assembly of this
complex requires at least 15 additional factors, being NDUFAF6 one of
them [19,20]. NDUFAF6 participates in the first stages of the assembly
of respiratory complex I and is associated with biogenesis of the mtDNA
encoded subunit p.MT-ND1 [21,22].
Defects in NDUFAF6, initially considered a rare cause of LS
[21,23,24] were recently identified in five Leigh syndrome Japanese
patients with nuclear encoded respiratory chain complex defects
[11,25]. However, little clinical information is available for the ma-
jority of cases, which hampers clinical recognition.
Our aim is to perform a deep phenotype characterisation in a ped-
igree of 3 siblings with compound heterozygous NDUFAF6 mutations
presenting with isolated dystonia and striatal necrosis, and to discuss
clinical, biochemical and genetic data in the context of a literature re-
view on NDUFAF6 patients. Moreover, we confirmed that the mutant
phenotype can be rescued by genetic complementation in patient fi-
broblasts, providing conclusive evidence for the pathogenicity of the
mutations.
2. Material and Methods
2.1. Patients
The proband of this kindred was identified from a cohort of 34
children with movement disorders and basal ganglia necrosis on MRI,
which were defined as hyper signal intensity on T2/FLAIR, restricted
diffusion on DWI/ADC sequences (acute phase), or T1 hypo-intensity,
volume loss or cavitation (chronic phase) in the putamen, caudate,
pallidum or subthalamus.
This study was approved by the Ethics Committee of the Vall
d'Hebrón Research Hospital in Barcelona, Spain. Blood samples, muscle
biopsy and fibroblasts from patient 1 were collected with the approval
of the Institutional Review Board at Hospital Virgen del Rocio in
Sevilla, Spain. Informed consent from patients' guardians was collected.
2.2. Genetic analysis
Total DNA was extracted from blood samples using the MagnaPure
system (Roche Applied Science, IN, USA). A customised gene panel for
movement disorders was designed using the Sure Design Tool (Agilent
Technologies, Santa Clara, CA, USA). This panel included 241 genes
linked to the following phenotypes: [1] LS due to mitochondrial defects;
[2] Leigh-like syndrome due to inborn errors of intermediate metabo-
lism; and [3] other phenocopies. Library construction was performed
according to manufacturer's protocol using HaloPlex technology. Se-
quencing was carried out on MiSeq sequencer (Illumina, San Diego, CA,
USA). Data processing, variant calling and variant annotation were
done by DNAnexus platform and Variant Studio software. The average
of mean-coverage in the sample gene panel was 95.4% for a read depth
of 20×. Filtering was performed by minor allele frequency < 1%
(extracted from ExAC general population database where 66,664 alleles
were analysed from European non-Finnish population) and possible
pathogenicity based on mutation effects (frameshift, insertions dele-
tions, missense, stop gain and splice site regions). Variant validation
and segregation studies were done by polymerase chain reaction (PCR)
with Sanger sequencing using the Big Dye Terminator Cycle Sequencing
System (Applied Biosystems). Primers for validation of the identified
change in NDUFAF6 were forward primer 5′-CCATGTCCATGGTGATT
TGT-3′ and reverse primer 5′-GAAGGCTTTAGTGCTAAACTGG-3′. The
NDUFAF6 ‘canonical’ sequence (NCBI: NM_152416.3; NP_689629.2)
was amplified from retro-transcribed total RNA extracted from control
and patient 3 fibroblasts and cloned using TOPO-Cloning (Thermo
Fisher Scientific) as in [26].
2.3. Mitochondrial parameters
Spectrophotometric assay for complexes of the respiratory chain in
muscles was performed according to previously described methods
[27]. Mitochondrial adenosine triphosphate (ATP) levels were mea-
sured 6 times as described previously [28] using the CellTiter-Glow
Luminiscent Cell Viability Assay (Promega). In-gel activity staining of
respiratory complexes was carried out as previously reported [29].
2.4. Complementation assay on patient fibroblasts
Control and patient-derived skin fibroblasts were grown at 37 °C in a
5% CO2 atmosphere in high-glucose Dulbecco's modified Eagle's
medium (DMEM) (Gibco-Life Technologies), supplemented with 10%
foetal bovine serum (FBS from Gibco). For neomycin-resistant cells, a
final concentration of 1 μg/mL in the medium was used.
The wild-type NDUFAF6 cDNA (NM_152416.3) was cloned into the
lentiviral expression vector pWPXLd-ires-NeoR, a modified version of
pWPXLd (Tronolab, Addgene #12258). Lentiviral particles were gen-
erated, and transduction was performed as described (https://www.
addgene.org/tools/protocols/plko/#E). Transduced cells were selected
for neomycin resistance 24 h after the transduction.
NDUFAF6 mRNA levels were determined by reverse transcription
quantitative polymerase chain reaction (RT-qPCR) assay in a
LightCycler 2.0 system (Roche), using FastStart DNA MasterPLUS SYBR
Green I (Roche).
Blue native polyacrylamide gel electrophoresis (BN-PAGE) was
performed as previously described [30].
For immunodetection, anti-NDUFAF6 (Sigma, # HPA050545), anti-
NDUFS3 (Thermo Fisher Scientific, #), anti- NDUFA9 (Thermo Fisher
Scientific, # 459100), anti- UQCRC2 (Abcam, # ab14745), anti- p.MT-
CO1 (Thermo Fisher Scientific, # 459600), anti-SDHA (Thermo Fisher
Scientific, #459200) and anti-Actin (Sigma, #A 2066) antibodies were
used. Chemiluminescence, image acquisition was performed using the
amersham imager 600 system.
3. Results
3.1. Case report
The 3 siblings were conceived from healthy non-consanguineous
Spanish parents. They were born at term after spontaneous delivery,
birth weights were between 2.860 and 3.422 g. and perinatal history
was unremarkable in all cases. Early psychomotor milestones were on
average, and they walked unaided between 12 and 15months. Initial
concerns appeared between the age of 17months and 2.5 years with toe
walking and speech difficulties. Neurological deterioration was in-
sidious, progressing to generalised dystonia and gait loss between the
age of 3 and 6 years. Currently, patients are 11, 8 and 6 years old, they
have prominent oromandibular and bulbar involvement causing speech
difficulties (i.e., dysarthria, stuttering) and dysphagia. None of them
had ever experienced episodes of acute encephalopathy/deterioration
with fever or intercurrent infections. Plasma amino acids, lactate and
urine organic acids concentrations were normal in the first 2 patients,
(P1 and P2) and were not performed in the youngest (P3). They re-
ceived treatment with mitochondrial cofactors, including thiamine and
biotin, as well as trihexyphenidyl and L-dopa for dystonia, without
clinical improvement. The clinical phenotype and progression of the 3
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siblings is reported in Video 1.
Brain MRI of the three siblings is shown in Fig. 1. Early signs of
compromise are shown in patient P3 fourteen months after the onset of
dystonia, with acute lesions in the putamen in a concentric distribution,
cytotoxic edema and apparently normal volume. Brain MRI in P2 at
10 weeks of age when the patient was asymptomatic was normal. A
second MRI performed at 3 years and 4months showed T2 hyper-in-
tensity in the putamen with partial involvement of the outermost part
of the body of both caudates, and also affecting the grey matter bands'
communicating with both nuclei. In DWI, the putamen is observed to
have concentrical distribution cytotoxic edema. Serial brain MRIs were
performed in patient P1 at 5 and 8 years, showing lesions in the pu-
tamen extending to the whole body of caudate nucleus, hypertrophy
and ectasia of lenticulostriate arteries, cystic patchy areas and reduced
volume along the entire putamen nucleus axial view, and progression to
prominent atrophy and volume loss of the whole caudate and the pu-
tamen. Brain magnetic resonance spectroscopy (MRS) revealed an in-
verted doublet in long TE spectroscopy, reflecting lactate and low levels
of N-acetylaspartate (NAA) in both the putamen and caudate.
Brain auditory and visual evoked potentials were normal for the first
2 patients and not performed in the third. Sensory and motor nerve
conductions were characteristic for peripheral demyelinating involve-
ment in P2. Muscle biopsy showed nonspecific myopathic changes in
the absence of mitochondrial proliferation in P1 at 5 years, and no
structural alterations in P2. Spectrophotometric measure of respiratory
complex enzymatic activity in muscle demonstrated isolated MRC
complex I deficiency in P1 (60% of activity) (8.88 nmol/CS Units, re-
ference value 15–80 nmol/CS Units) and normal activity in P2.
3.2. Molecular analysis
We identified in the probandus (P1, Fig. 2B) a frameshift novel
change at genomic coordinate chr8:96057849_96057853 according to
hg19 reference genome (c.554_558delTTCTT; p.Tyr187AsnfsTer65) and
a missense change previously reported in 2 unrelated patients
(c.371 T > C; p.Ile124Thr) in the NDUFAF6 gene [25]. Both mutations
Fig. 1. Brain magnetic resonance imaging (MRI) in NDUFAF6 mutated patients. P3. MRI at 2 years and 7months of age (a–e). Lenticulostriate arteries ectasia is seen
on axial postcontrast T1WI (a). Axial T2WI (b) and FLAIR (c) images add putaminal hypersignal (white arrows), with sparing of its caudal edge and with apparently
normal volume. High signal intensity in DWI (d), with low ADC signal (not shown), represents abnormal restricted diffusion within both putamen nuclei (white
arrowheads), with a concentrical distribution. Caudate nuclei are spared, better seen on coronal T2WI (e). Slight compensatory ventriculomegaly is also depicted.
P2 MRI at 3 years and 4months of age (f–j). Axial FLAIR images (f, g) show putaminal hypersignal with mild reduction in volume and central hyposignal reflecting
cavitation. On DWI (h, i) putamen is observed with central patchy hypointensity but anterior and posterior hyperintensity (concentrical distribution cytotoxic edema)
(black arrowheads), with low ADC values (not shown). Partial involvement of the most outer part of the body of both caudates, more prominent in the left, and also
affecting the grey matter caudate-putamen's bands (black arrows) better observed on coronal T2WI (j).
P1 MRI at 5 years of age (k, l) and follow-up at 8 years of age (m–o). Axial T2WI (k) and axial FLAIR (l) images depict hyperintensity and moderate volumen reduction
of the whole putamen, and hypersignal and mild enlargement of the anterior part of the body of the caudate. Axial FLAIR (m) and coronal T2WI (o) show atrophy of
the whole caudate and putamen nuclei, with mild compensatory frontal horns' dilation. Axial DWI (n) shows hypointensity within the posterior putamen (high ADC
values, not shown), reflecting cavitation, and ventral putamen and caudate nucleus hypersignal (with high ADC values, not shown) due to T2 shine-through effect
(white dashed arrows).
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were in highly conserved regions according to UCSC Genome Browser
and Clustal Omega software. The frameshift change was classified as
pathogenic by Mutation Taster protein predictor, and it was not found
in HGMD, dbSNP 1000 Genome project, ExAC database or CIBERER
Spanish Variant Server. No other mutations were identified in other
genes. SANGER analysis (Fig. 2A) showed that the other two affected
siblings (P2, P3) carried both changes, the father carried the missense
mutation and the frameshift variant came from the mother, consistent
with an autosomal recessive mode of inheritance. Human NDUFAF6
mutations described so far are also reported (Fig. 2D).
Amplification and cloning of NDUFAF6 cDNA from P3 fibroblasts
yielded 2 sequences. One carried the missense change previously re-
ported as a pathologic mutation (c.371 T > C; p.Ile124Thr). The other
sequence carried the frameshift novel change (c.554_558delTTCTT;
p.Tyr187AsnfsTer65) (Fig. 2C). These results confirmed the biallelic
nature of the variants.
3.3. Literature review of patients with NDUFAF6 deficiency
Our patients were compared with 11 previously reported cases with
NDUFAF6 defects and LS phenotype [23,25,45–47] (Table 1). Mean age
at onset of these children was 24 (0–72) months. All patients were alive
at the time of publication except for 1 case that died at 34months [23].
One patient presented with an acute metabolic decompensation trig-
gered by acute febrile illness, whereas onset of neurological features
was insidious in the rest of the cases. All patients suffered from neu-
rological regression, and the majority developed signs of basal ganglia
dysfunction (dystonia, rigidity, tremor). Other neurological features
included ataxia, seizures, myopathy and peripheral neuropathy. All
patients showed basal ganglia lesions on MRI, predominantly affecting
the putamen and caudate. T2-hyperintensities in dentate nuclei and
superior cerebellar peduncles were observed in three patients [45,46].
One patient showed a more diffuse brain involvement, with lesions
affecting the parietal cerebral white matter and the dorsal pons [23].
Regarding biochemical findings, 4 out of 14 cases showed increased
blood lactic acid levels. The activity of RCC was reduced in fibroblasts
(n=9, 40–86%) and muscle (n=6, 28–80%).
3.4. Patient mutations are associated with the absence of the NDUFAF6
protein and reduced activity and levels of mature complex I
The mitochondrial ATP levels measurements revealed that P3-de-
rived primary fibroblasts displayed 40% reduction in mitochondrial
ATP levels relative to control cells (Fig. 3A). NDUFAF6 transcript levels
in the patient were significantly reduced to 62% of the control (Fig. 3B).
This reduction is probably due to nonsense mediated mRNA decay since
the frameshift mutation in one allele of the patient introduces a pre-
mature stop codon into the NDUFAF6 mRNA. Protein lysates extracted
from a control, (C), an immortalised control (Ci) and P3 cells, were
analysed by WB using a specific anti-NDUFAF6 antibody. NDUFAF6
cross-reacting material was detected as a 32 kDa band in control fi-
broblasts, but was almost undetectable in the patient (Fig. 3C), in-
dicating that patient mutations are associated with a strong reduction of
the NDUFAF6 protein.
In order to determine if the absence of NDUFAF6 caused a decreased
in the activity and quantity of complex I, BN-PAGE analysis was per-
formed. BN-PAGE followed by in-gel activity (IGA) staining of re-
spiratory complexes of muscle samples from patients P1, and P2
Fig. 2. Family pedigree and segregation analysis of the NDUFAF6mutations within the family. (A) Sanger confirmation of the missense (c.371 T > C) and frameshift
(c.554_558delTTCTT) mutations in the NDUFAF6 gene; (B) family pedigree; (C) amplification and cloning of patient NDUFAF6 cDNA; (D) human NDUFAF6 described
mutations.
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(Fig. 3D) and fibroblasts from P3 (Fig. 3E) showed decreased CI enzy-
matic activity relative to CII.
BN-PAGE followed by Western blot analysis using specific anti-
bodies revealed that the amount of mature complex I in P3-mitoplasts
was dramatically decreased compared to that of the control, consistent
with the complex I activity defect detected in the 3 siblings. Mature
complex II, complex IV and complex III dimer were present at only
slightly decreased levels compared to the control (Fig. 3F).
3.5. Complementation assay on patient fibroblasts
In order to test functional complementation, wild-type NDUFAF6
was transduced in patient and control fibroblasts. Robust over-
expression of NDUFAF6 was detected at both mRNA and protein levels
(Fig. 3B and G). This was associated with the recovery of a normal
amount of CI assembly in patient cells. In contrast, expression of wild-
type NDUFAF6 in control fibroblasts did not significantly modify the
mature complex I amount (Fig. 3H).
Increased levels of mature complex I correlated with patient re-
covery of complex I in-gel activity (Fig. 3E), linking NDUFAF6 gene
with the biochemical defects.
4. Discussion
We report a pedigree of 3 siblings with progressive dystonia and
striatal necrosis harbouring compound heterozygous mutations in the
NDUFAF6 gene. These children manifested with gait dystonia and
speech difficulties in early childhood after a period of normal neuro-
development. Gradual progression of symptoms led to generalised
dystonia, gait loss, severe dysarthria and total dependence on activities
of daily living in a period of 1.5 to 4 years. No systemic features of
mitochondrial disorders were observed, and lactic acid, serum alanine
levels and organic acids were normal in blood and urine.
The suspicion of mitochondrial disorders was based on neuroima-
ging studies, which detected cytotoxic oedema in the neostriatum on
DWI and a lactate peak on MRS, and on inconsistent results in the ac-
tivity of MRC complex I in muscle by spectrophotometric assay in two
siblings. Massive parallel sequencing recognised the previously re-
ported missense change c.371 T > C and the novel frameshift
c.554_558delTTCTT variant in the NDUFAF6 gene, encoding an as-
sembly factor of NADH-ubiquinone oxidoreductase. Further investiga-
tions demonstrated reduced assembly of mature complex I and reduced
complex I enzymatic activity by BN-PAGE and in-gel activity (IGA)
staining.
The novel variant c.554_558delTTCTT is a frame-shift mutation that
is expected to result in a truncated translation product. Our patients'
mutations were associated with a strong reduction in the steady-state
levels of NDUFAF6 protein. NDUFAF6 transcript levels in the patient
were also reduced, suggesting that the absence of transcripts from this
allele contributed to the reduction of NDUAFAF6 protein levels.
Genetic complementation is a powerful tool to obtain strong evi-
dence of pathogenicity of mutations [31]. Remarkably, the mutant
phenotype was rescued in P3 fibroblasts by the canonical version of the
NDUFAF6, thus demonstrating the pathogenicity of the NDUFAF6 ge-
netic variants detected in the 3 siblings.
Regarding neuroradiological investigations, the 3 siblings showed
symmetric and bilateral cytotoxic lesions in the putamen nuclei, which
started in its upper, lateral and central part, spreading in a concentric
and centrifugal manner to its inferior and medial region, through the
grey matter bands to the anterior part of the caudate nucleus body and
then to the head ventrally and to the tail dorsally. The first grey matter
structures affected developed diffusion restriction. The lesions pro-
gressed to volume loss and cavitation in the older siblings, more pro-
minent in the putamen than in the caudate, and to compensatory
ventricular enlargement. T2WI and T1WI after contrast media admin-
istration showed enhancement of the lenticulo-striate arteries, probablyTa
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corresponding to vascular hypertrophy and proliferation in response to
hypoperfusion and deoxygenation, a scenario previously reported in
anatomopathological descriptions of LS [32–34]. Of note, none of the
patients presented with pallidal compromise.
By reviewing previous patients identified with homozygous or
combined heterozygous mutations in NDUFAF6 we could demonstrate a
homogeneous phenotype consisting of an insidious onset movement
disorders associated with neurological regression before the age of
6 years. All patients showed basal ganglia neurodegeneration on MRI.
In two patients, a similar progression of basal ganglia abnormalities was
reported with acute restricted diffusion lesions in the putamen
spreading to the caudate and leading to atrophy and cavitation [45,46].
Three patients associated lesions in the cerebellar peduncles and den-
tate nuclei, and one single case showed involvement of the pons and
parietal white matter. The vast majority of cases (11/12) showed de-
creased activity of RCC I in fibroblasts and/or muscle.
Brain lesions in our patients fulfilled the radiological criteria of
bilateral striatal necrosis (BSN). This entity defines a group of disorders
presenting with movement disorders and bilateral degeneration of the
neostriata (caudate and putamen) [35–37]. BSN encompasses a sub-
group of LS patients (MIM 256000), in whom the association with
brainstem involvement and lactate peak in MRS is highly characteristic,
as compared to other aetiologies [39]. Also, other brain areas may be
affected in LS patients, the most common being the cerebellum, tha-
lamus, spinal cord and white matter, stroke-like lesions and cortical and
cerebellar atrophy (BSN plus) [38–40].
Our results confirm that NDUFAF6 may be included in a narrow
subgroup of LS patients with brain lesions limited to the neostriata
(isolated BSN), together with genetic thiamine metabolism defects [3],
mitochondrial DNA genetic defects (ND1, ND6 and Complex V defi-
ciency) [41,42] and NDUFV1 mutations causing complex I deficiency
[43,44]. These defects may show bilateral and symmetric involvement
of the putamen and caudate, with swelling and cytotoxic oedema, and a
lactate peak in the acute phase. Also, progression to atrophy and ca-
vitation has been reported, similar to patients with NDUFAF6-related
LS [35].
Etiologic diagnosis of early onset dystonia with BSN is a diagnostic
challenge for paediatric neurologists due to the uniform and unspecific
clinical and radiological features, the lack of biomarkers, and the in-
creasing number of underlying genetic conditions described so far.
Mitochondrial energy generation defects are the most frequent genetic
conditions in children with dystonia and BSN [9]. Among them, genetic
defects in thiamine transport and metabolism are of utmost importance
due to the potential clinical benefit of biotin and thiamine supple-
mentation [3,4]. Other genetic defects leading to neostriatal lesions
were recently reviewed by Tonduti et al. [35] and included glutaric
aciduria type 1 and other organic acidurias, Aicardi-Goutières syn-
drome caused by ADAR1 mutations, gangliosidosis type 2, sulfite oxi-
dase and molybdenum cofactor deficiency, Wilson's disease, Alex-
ander's disease, giant axonal neuropathy, H-ABC syndrome
Fig. 3. Mitochondrial ATP synthesis, in-gel activity
stain of respiratory complexes and Western blot
(WB) immunodetection.
(A) Mitochondrial ATP levels in primary fibroblasts.
Statistical significance (unpaired t-test) is shown,
***= p < .001 vs C. (B) qPCR quantitation of
NDUFAF6 mRNA expression in fibroblasts and
NDUFAF6-transduced fibroblasts. Statistical sig-
nificance (unpaired t-test) is shown, *= p < .05,
***= p < .001. (C) WB immunodetection of so-
dium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) in fibroblasts (100 μg of total
protein extract were loaded per lane). (D) In-gel ac-
tivity staining of respiratory complexes in muscle
samples of P1 and P2. (E) In-gel activity staining of
complex I in fibroblasts and in NDUFAF6-transduced
fibroblasts. (F) WB immunodetection of BNGE in fi-
broblasts and in NDUFAF6-transduced fibroblasts.
(G) WB immunodetection of SDS-PAGE in fibroblasts
(60 μg of total cellular extract) and NDUFAF6-trans-
duced fibroblasts (10 μg of total cellular extract). (H)
WB immunodetection of BNGE in fibroblasts and
NDUFAF6-transduced fibroblasts. Ci: immortalised
control fibroblasts; C: control primary fibroblasts;
P3: patient 3 primary fibroblasts.
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(hypomyelination with atrophy of basal ganglia and cerebellum),
Huntington's disease and some neurodegeneration with brain iron ac-
cumulation disorders.
5. Conclusion
NDUFAF6-related Leigh syndrome should be included in the dif-
ferential diagnosis of LS patients presenting with insidious onset dys-
tonia in early childhood, progressing from gait difficulties to general-
ised dystonia with predominant oromandibular involvement, dysphagia
and dysarthria. Clinical deterioration is associated with symmetric and
bilateral cytotoxic lesions in the putamen, with vascular hypertrophy
and proliferation of the lenticular-striate arteries, spreading to the
caudate, and progressing to cavitation and volume loss, fulfilling radi-
ological criteria of isolated striatal necrosis in the majority of cases.
Reduced assembly of mature complex I and reduced complex I enzy-
matic activity is characteristic, while systemic mitochondrial bio-
markers may be normal. Even when next generation sequencing tech-
niques permitted the identification of candidate variants, functional
genetic complementation assays allowed us to obtain conclusive evi-
dence for pathogenicity in this family.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2019.01.001.
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